Catalyst Brief

← Calendar

Readoutin 14d

Madrigal Pharmaceuticals, Inc. — Resmetirom

Phase 3 primary completion: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES).

Date
Dec 2026
Type
Readout
Indication
NASH

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Madrigal Pharmaceuticals, Inc.

  1. Mar2027